LD: Writing original draft, Supervision, Data curation
Headline results from ESSENCE, which formed the basis of that 2025 approval, included: About 63 percent of semaglutide-treated patients reached resolution of steatohepatitis without worsening of liver fibrosis at 72 weeks Approximately 37 percent showed measurable improvement in liver fibrosis (the scarring that drives long-term liver damage) Mean body-weight reduction reached roughly 10 percent over 72 weeks of weekly subcutaneous semaglutide Gastrointestinal symptoms (nausea, early fullness, mild diarrhea) were the most common side effects, generally manageable with gradual dose escalation Source: FDA Wegovy approval materials, 2025 (FDA Drugs) The SLIM LIVER Trial and What It Found in People with HIV The ESSENCE numbers above come from the general MASH population, not specifically from people living with HIV
Isoliquiritigenin (ISL), a type of flavonoid, has many health benefits but has poor bioavailability and stability and limits its application in clinical studies
If low we recommend shots (we have the highest quality methylcobalamin - I dont recommend the cheaper cyanocobalamin especially if you have methylating deficiency)
Since your body cant make its vitamin B12, you need to get it from external sources
